Evidence map›Paper›PMID 34911657›Full record

ReviewTrends in pharmacological sciences2022

Targeting intracellular protein-protein interactions with macrocyclic peptides.

Marina Buyanova, Dehua Pei

Open access · greenAbstract readReview
In one paragraph

Review in Trends in pharmacological sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Marina BuyanovaDepartment of Chemistry and Biochemistry, The Ohio State University, 484 West 12th Avenue, Columbus, OH 43210, USA.
Dehua PeiDepartment of Chemistry and Biochemistry, The Ohio State University, 484 West 12th Avenue, Columbus, OH 43210, USA. Electronic address: pei.3@osu.edu.
The Ohio State University · US

Funding

Development of Cell-Permeable Peptides and ProteinsR35GM122459 · NIGMS · OHIO STATE UNIVERSITY · PI Dehua Pei · 2017 to 2026
$5.1M
Macrocyclic Peptidyl Inhibitors of NEMO-IKK InteractionR01CA234124 · NCI · OHIO STATE UNIVERSITY · PI PEI, DEHUA, WANG, QIEN · 2019 to 2023
$2.1M
NCI NIH HHS R01 CA234124NIGMS NIH HHS R35 GM122459
6 · The paper itself

Abstract

Intracellular protein-protein interactions (PPIs) are challenging targets for traditional drug modalities. Macrocyclic peptides (MPs) prove highly effective PPI inhibitors in vitro and can be rapidly discovered against PPI targets by rational design or screening combinatorial libraries but are generally impermeable to the cell membrane. Recent advances in MP science and technology are allowing for the development of 'drug-like' MPs that potently and specifically modulate intracellular PPI targets in cell culture and animal models. In this review, we highlight recent progress in generating cell-permeable MPs that enter the mammalian cell by passive diffusion, endocytosis followed by endosomal escape, or as-yet unknown mechanisms.

Indexed as

PeptidesPeptides, CyclicAnimalsCell MembraneEndocytosisEndosomesHumansMammalsPeptidesPeptides, Cyclicbicyclic peptidecyclic peptidedrug discoveryintracellular biologicspermeabilityprotein-protein interaction

Identifiers

PMID34911657
PMCPMC8840965
OpenAlexW4200031091

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.